Reactivating hope for TP53-mutated acute myeloid leukaemia?

Lancet Haematol. 2023 Apr;10(4):e239-e240. doi: 10.1016/S2352-3026(23)00028-5.

Author

Gesine Bug¹

Affiliation

¹ Department of Medicine 2, Hematology and Oncology, Goethe University, 60590 Frankfurt, Germany; Frankfurt Cancer Institute, Goethe University, 60590 Frankfurt, Germany; German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz and German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address: g.bug@em.uni-frankfurt.de.

PMID: 36990618
DOI: 10.1016/S2352-3026(23)00028-5

No abstract available

MeSH terms

Humans
Leukemia, Myeloid, Acute* / genetics
Mutation
Tumor Suppressor Protein p53 / genetics

Substances

Tumor Suppressor Protein p53
TP53 protein, human